Genes & Cancer | Severe Herpesvirus Infection Beats Adult T-cell Leukemia/Lymphoma
Genes & Cancer, News
February 24, 2023“Although contracting herpes simplex or herpes zoster is unpleasant, the mechanism by which these herpesvirus infections can produce a therapeutic effect […]”
BUFFALO, NY- February 24, 2023 – A new editorial was published in Genes & Cancer on January 19, 2023, entitled, “Severe herpesvirus infection beats adult T-cell leukemia/lymphoma.”
In this recently published editorial, researcher Tatsuro Jo from the Japanese Red Cross Nagasaki Genbaku Hospital’s Department of Hematology discussed aggressive type adult T-cell leukemia/lymphoma (ATLL). ATLL caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection is associated with dismal survival, even after the approval of mogamulizumab (a monoclonal antibody for C-C chemokine receptor 4 antigen). A large number of genetic and epigenetic abnormalities as the results of the pleotropic effects of HTLV-1 Tax and HBZ reportedly are present in ATLL patients [1, 2], which may be the cause of their poor response to intensive chemotherapies.
The HTLV-1 sequence is completely distinct from the human genome, making the HTLV‑1 gene products highly immunogenic to humans and targets for the humoral and cellular immunity. Actually, antibodies against the HTLV-1 gag and env gene products are ubiquitously detected in HTLV-1 carriers. Furthermore, cytotoxic T lymphocytes (CTLs) against HTLV-1 Tax (TaxCTLs) are often observed in long-term survivors with ATLL treated with or without allogeneic hematopoietic stem cell transplantation. Thus, the activation of antitumor cellular immunity may play an important role among longterm survivors with ATLL, an intractable disease.
In patients with ATLL, the CD4/CD8 ratio in T lymphocytes is often inverted due to a decrease in CD4-positive T lymphocytes, including regulatory T lymphocytes (Treg), after treatment with mogamulizumab. Conversely, we have noticed that the CD4/CD8 ratio is almost always inverted in long-term surviving ATLL patients in the pre-Mogamulizumab era. Furthermore, several of these patients developed herpesvirus infections, such as herpes zoster and herpes encephalitis, while their disease was controlled by chemotherapy and subsequently exhibited CD4/CD8 ratio reversal [3]. Herpesvirus infection has been reported to strongly activate host cellular immunity [4, 5].
“Although contracting herpes simplex or herpes zoster is unpleasant, the mechanism by which these herpesvirus infections can produce a therapeutic effect on refractory ATLL via the activation of the host’s cellular immunity is extremely interesting and worth further study”
Read more: Editorial DOI: https://doi.org/10.18632/genesandcancer.228
Correspondence: Tatsuro Jo – Email: tjmahamayurijnt@gmail.com
Keywords: adult T-cell leukemia/lymphoma, HTLV-1, Tax, varicella zoster virus vaccination
VISIT GENES & CANCER YOUTUBE CHANNEL FOR MORE VIDEOS
About Genes & Cancer: Genes & Cancer covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, Genes & Cancer also aims to attract papers in the areas of genomics, drug development and systems biology.
To learn more about Genes & Cancer, visit www.genesandcancer.com and connect with us on social media:
For media inquiries, please contact: media@impactjournals.com.
